Navigation Links
Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
Date:3/29/2011

als of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM™ are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no oblig
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
10. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
11. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Expanding in a big way into ... Biomed Inc. recently inked a deal with Arthur ... Ltd. , the largest endodontic distributor in Japan. The ... for Avalon Biomed, which manufactures Grey MTA Plus® and ... cements that have won renown from dentists around the ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
(Date:5/27/2015)... 2015  Ceres, Inc. (Nasdaq: CERE ), an ... for a genetic sequence derived from soybean, covering uses ... development and plant transformation. The company believes that its ... are the target of a class of commercial herbicides. ... license to the innovation, including an opportunity for exclusivity ...
(Date:5/27/2015)... Caris Life Sciences®, a leading biotechnology company ... announced it has appointed the Levine Cancer Institute, part ... in the Caris Centers of Excellence for Precision Medicine ... one of the largest cancer care providers throughout the ... annually. Derek Raghavan , M.D., Ph.D., President of ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Cubresa Launches Simultaneous PET/MRI Technology 2Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4
... , , , ... Inc. (Nasdaq: ITMN ) today announced that it will ... help further the research of inherited genetic factors that may play ... researchers at National Jewish with access to DNA collected from patients ...
... ... announced that Henry "Pete" Linsert, Jr. has joined its Board of Directors. , ... Alachua, FL (PRWEB) September ... joined its Board of Directors., , ,Mr. Linsert is President and CEO of Columbia ...
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
Cached Biology Technology:InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 3NovaMin Technology Inc. Welcomes New Board Member 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... A new tumor-suppressor gene has been discovered by a team ... the gene works with another tumor suppressor to control tissue ... in the 11 March 2005 issue of the journal Cell. ... controlled both during normal development and during the formation of ...
... three months after deciding to create an electronic ... registry and results database using an independent host, ... can be accessed by anyone, anywhere, with no ... patients and healthcare providers ready access to information ...
... such injury as stroke or trauma depends on a particular ... brain chemical acetylcholine, researchers led by James Conner and Mark ... Their finding in rats could help enhance rehabilitation to recover ... or other treatments to enhance the "cholinergic system." , The ...
Cached Biology News:New tumor-suppressor gene discovered 2New tumor-suppressor gene discovered 3New tumor-suppressor gene discovered 4Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3Brain-injury rehabilitation depends on acetylcholine circuitry 2
... DNA is an ideal small concentrator for ... capable of removing water and organic solvents ... tubes, microplates, vials and round bottom flasks. ... the busy lab. ,The built-in special runs ...
... The Brownlee Precision Model 440 incorporates ... circuitry in a friendly easy-to-use instrument. Each ... amplifier, an 8-pole Bessel lowpass filter, a ... output offset controls. A control knob sets ...
... versatile & modular instrument which can be used ... Extracellular, Transducer & Multi-channel Isolated Amplification ... Supply unit (NL900D) forms the heart of every ... by this unit, but wiring within the case ...
Rat Epidermal Keratinocytes (REK) (>500,000 cells)...
Biology Products: